# OnCo record nct05934331 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05934331/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05934331", "NCT05934331" ;
  schema:name "A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study"@en ;
  schema:description "A phase 2 trial of LM-302, Toripalimab, Capecitabine, Nivolumab, Rivoceranib (apatinib) and Gemcitabine in advanced solid tumours, run by LaNova Medicines Zhejiang Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05934331/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05934331> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-07-27" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/lm-302/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/rivoceranib/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/lanova-medicines/> .